Cite

HARVARD Citation

    Rogers, S. et al. (2017). Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. Cancer investigation. pp. 552-561. [Online]. 
  
Back to record